REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that results from its completed Phase 2 study evaluating burixafor, a small molecule CXCR4 antagonist, will be featured in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place... Read More

Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development Expertise REDWOOD CITY, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today shared recent progress for its... Read More

REDWOOD CITY, Calif. / Aug 08, 2025 / Business Wire / Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended June 30, 2025. Second Quarter 2025 Financial Results Cash Position : Cash and cash equivalents were $7.9 million as of June 30, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense : Research and development... Read More

REDWOOD CITY, Calif. / Aug 04, 2025 / Business Wire / Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR) a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that, as of July 1, 2025, the Company regained compliance with the periodic filing requirement for The Nasdaq Stock Market under Listing Rule 5250(c)(1) (the “Rule”) based on the filing of its periodic reports... Read More

Topline results expected H2 2025 REDWOOD CITY, Calif. / Aug 01, 2025 / Business Wire / Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in its ongoing Phase 2 clinical trial ( NCT05561751 ) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in... Read More

REDWOOD CITY, Calif. / Jun 27, 2025 / Business Wire / Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended March 31, 2025. First Quarter 2025 Financial Results Cash Position : Cash and cash equivalents were $10.4 million as of March 31, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense : Research and development... Read More

REDWOOD CITY, Calif. / May 28, 2025 / Business Wire / Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2025 notifying the Company that, as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q by May 20, 2025 for the quarterly period ended March 31, 2025 (the “Form 10-Q”), the... Read More

Topline results expected H2 2025 REDWOOD CITY, Calif. / May 05, 2025 / Business Wire / Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed patient enrollment in its ongoing Phase 2 clinical trial ( NCT05561751 ) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple... Read More

REDWOOD CITY, Calif. / Apr 14, 2025 / Business Wire / Exicure, Inc. (Nasdaq: XCUR) today announced that GPCR Therapeutics USA, a subsidiary of Exicure Inc., has dosed the 19th patient in its ongoing Phase 2 clinical trial evaluating GPC-100 (burixafor), a small molecule CXCR4 inhibitor, for the mobilization of stem cells in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT) (NCT05561751). The... Read More

REDWOOD CITY, Calif. / Apr 11, 2025 / Business Wire / Exicure, Inc. (Nasdaq: XCUR) today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. (“Exicure”) is planning for a clinical trial in Acute Myeloid Leukemia (AML) with GPC-100. The company believes that GPC-100, when paired with modern AML treatment regimens, can further improve outcomes in this high unmet need clinical... Read More

CHICAGO / Mar 18, 2025 / Business Wire / Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring... Read More

CHICAGO / Mar 13, 2025 / Business Wire / Exicure, Inc. (Nasdaq: XCUR) today announced that the Australian Patent Office has issued Patent No. 2018388302, titled "GPCR Heteromer Inhibitors and Uses Thereof." This patent covers the company’s innovative combination approach to cancer treatment, specifically targeting CXCR4 and GPCRx. The newly granted patent supports Exicure’s ongoing Phase 2 clinical trial (NCT05561751), which... Read More

CHICAGO / Jan 23, 2025 / Business Wire / Please replace the release dated January 22, 2025 with the following corrected version due to multiple revisions. The updated release reads: Exicure, Inc. (Nasdaq: XCUR, “the Company”, “Exicure”), today announced that on January 19, 2025, Exicure Inc. (“the Company”) entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation (“GPCR”), pursuant to which... Read More

CHICAGO / Jan 22, 2025 / Business Wire / Exicure, Inc. (Nasdaq: XCUR, “the Company”, “Exicure”), today announced that on January 19, 2025, Exicure Inc. (“the Company”) entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation (“GPCR”), pursuant to which the Company acquired from GPCR all of the issued and outstanding equity securities of GPCR Therapeutics USA Inc., a California corporation... Read More

CHICAGO / Dec 26, 2024 / Business Wire / Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc. (“GPCR Therapeutics”) on December 24, 2024, aimed at the acquisition of GPCR USA, a subsidiary of GPCR Therapeutics, and the technology transfer and collaborative research on GPCR Therapeutics’ ongoing drug development pipelines. Through... Read More

CHICAGO / Dec 21, 2024 / Business Wire / Please replace the release dated December 20, 2024 with the following corrected version due to multiple revisions. The updated release reads: EXICURE ANNOUNCES SHAREHOLDERS APPROVE THE $8.7 MILLION EQUITY FINANCING AND REPORTS EXECUTIVE MANAGEMENT AND BOARD CHANGES Exicure, Inc. (Nasdaq: XCUR, “the Company”, “Exicure”), today announced that in connection with the change of control... Read More

CHICAGO / Dec 20, 2024 / Business Wire / Exicure, Inc. (Nasdaq: XCUR, “the Company”, “Exicure”), today announced that in connection with the change of control transaction approved by the stockholders at the Special Meeting of the Stockholders on December 17, 2024 (the “Change of Control”), the stockholders of the Company approved a second investment of $8.7 million from HiTron Systems Inc. (“HiTron”), a publicly listed... Read More

CHICAGO / Nov 14, 2024 / Business Wire / Exicure, Inc. (Nasdaq: XCUR, the "Company") has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was... Read More

CHICAGO / Sep 18, 2024 / Business Wire / Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (“Panel”) granted an extension to continue the Company’s listing subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by November 14, 2024. The Company... Read More

CHICAGO / Sep 09, 2024 / Business Wire / Exicure, Inc. (Nasdaq: XCUR, the “Company”) announced today that it has entered into an agreement with plaintiffs to settle Colwell v. Exicure, Inc. et al., Case No. 1:21-CV-06637, a previously disclosed securities class action lawsuit pending in the United States District Court for the Northern District of Illinois (the “Court”). The settlement is subject to Court approval, and... Read More

CHICAGO / Aug 26, 2024 / Business Wire / Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Company expects that the Reverse Stock Split will become effective at 5:00 pm on Tuesday, August 27, 2024, and its common stock will begin trading on a split-adjusted basis at the open of trading on... Read More

CHICAGO / Aug 19, 2024 / Business Wire / Exicure, Inc. (Nasdaq: XCUR, the "Company") announced today that its Special Meeting of Stockholders (the "Special Meeting"), initially scheduled for August 15, 2024 and adjourned and reconvened on August 19, 2024, has been adjourned again for the purpose of soliciting additional votes with respect to the proposal described in the Company's definitive proxy statement for the Special... Read More

CHICAGO / Aug 15, 2024 / Business Wire / Exicure, Inc. (Nasdaq: XCUR, the "Company") announced today that its Special Meeting of Stockholders (the "Special Meeting") scheduled for and convened on August 15, 2024 has been adjourned for the purpose of soliciting additional votes with respect to the proposal described in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange... Read More

CHICAGO / Aug 13, 2024 / Business Wire / Exicure, Inc. (Nasdaq: XCUR, the "Company"), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was... Read More

CHICAGO / Aug 08, 2024 / Business Wire / Anna Chukaeva has been appointed as Senior Vice President, Head of Corporate Development and Bioinformatics of Exicure, Inc. (“the Company”) (Nasdaq: XCUR). Anna will spearhead investments, acquisitions, and strategic partnerships. She will also push into leveraging data and AI for drug discovery and diagnostics. Anna was the co-founder, President and COO of Carta Healthcare, an AI... Read More

CHICAGO / Aug 01, 2024 / Business Wire / Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on July 31, 2024, the Company received formal notice that the Nasdaq Hearings Panel (“Panel”) has determined to continue the Company’s listing subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by September 16, 2024. The Company is... Read More

CHICAGO / Jun 17, 2024 / Business Wire / Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was... Read More

CHICAGO / Jun 06, 2024 / Business Wire / Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring... Read More

CHICAGO / May 23, 2024 / Business Wire / Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received notice of a delisting determination (the “Staff Delisting Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”). The Staff Delisting Determination notified the Company that since it has not yet filed its Form 10-K for the year ended December 31, 2023... Read More

CHICAGO / May 16, 2024 / Business Wire / Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring... Read More

CHICAGO / Apr 22, 2024 / Business Wire / Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”), the Company is not in compliance with Nasdaq... Read More

CHICAGO / Feb 05, 2024 / Business Wire / Exicure, Inc. , (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. ("Bluejay") and Exicure, Inc. ("Exicure") entered into a patent license agreement to develop cavrotolimod for potential... Read More

CHICAGO / Nov 28, 2023 / Business Wire / Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on November 22, 2023 notifying the Company that, as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 (the “Form 10-Q”), the Company is not in... Read More

CHICAGO / Aug 23, 2023 / Business Wire / Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that, effective as of August 21, 2023, Paul Kang, a Class III director, was appointed as Chief Executive Officer of the Company and Jiyoung Hwang, a Class I director, was appointed as Chief... Read More

CHICAGO / Aug 11, 2023 / Business Wire / Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring... Read More

CHICAGO / Jul 14, 2023 / Business Wire / Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring... Read More

CHICAGO / May 26, 2023 / Business Wire / Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore strategic alternatives to maximize stockholder value, and as part of such ongoing effort, previously announced the appointment... Read More

CHICAGO / May 19, 2023 / Business Wire / Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on May 17, 2023 notifying the Company that, as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the “Form 10-Q”), the Company is not in compliance with... Read More

CHICAGO / May 04, 2023 / Business Wire / Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that it has invested in Cyworld Z Co. Ltd. (“Cyworld Z”), the operator of a Korean SNS platform "Cyworld" through the purchase of $1 million aggregate principal amount of convertible bonds... Read More

CHICAGO / Apr 27, 2023 / Business Wire / Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that, effective as of April 26, 2023, Jung-Sang (Michael) Kim was appointed as Chief Executive Officer and Chief Financial Officer of the Company and a Class II director of the Company’s board... Read More

CHICAGO / Mar 27, 2023 / Business Wire / Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial results for the year ended December 31, 2022 and provided an update on its business strategy and corporate progress. Corporate Update As previously reported, in September 2022, we... Read More

CHICAGO / Feb 24, 2023 / Business Wire / Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced the closing of the previously-announced private placement transaction with CBI USA, Inc. (“CBI USA”) effective February 24, 2023. In connection with the closing of the private placement... Read More